Trillium Therapeutics (TRIL) Given a $10.00 Price Target at HC Wainwright
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) has been assigned a $10.00 price objective by equities research analysts at HC Wainwright in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 31.58% from the company’s current price.
Several other research firms have also recently commented on TRIL. Zacks Investment Research cut shares of Trillium Therapeutics from a “buy” rating to a “hold” rating and set a $8.75 target price for the company. in a research note on Thursday, January 11th. ValuEngine cut shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $12.25.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at $7.60 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. Trillium Therapeutics has a one year low of $4.15 and a one year high of $13.30. The firm has a market cap of $100.58, a price-to-earnings ratio of 2.07 and a beta of 12.65.
ILLEGAL ACTIVITY WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/03/14/trillium-therapeutics-tril-given-a-10-00-price-target-at-hc-wainwright.html.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.